Onconetix Inc (ONCO) News

ONCO,new 52=week low

ONCO, 10Q due DEC 13

onco dolla bound

ONCO..............................................a/h

ONCO AH

ONCO: Thanks for that interpretation! (We all recall when RS's DESTROYED any stock's PRICE.)

All out 6.18 risky pump with a hard dump coming

ONCO 6.20s-6.40s resistance zone 1 out 80% out of trade here next zone 6.80s much smaller chance

FUC ME...SHOULD HAVE BOUGHT THAT DIP...CLASSIC POST RS ACTION

Enjoy the brief reverse split pump they will need another one but probably will be bankrupt before. They have negative cash and tons of debt.

ONCO: And "HERE-WE-GO", and "HERE-WE-GO-AGAIN" --- down that lonely street of DREAMS that never ends??? (See 'CHART', below!! Nice song, too!!) Tailwind from that 9-24-24 (1-for-40) Reverse Split???

It almost appears that there is some other news that will be coming out. Anybody have any ideas?

BB

ONCO...HERE WE GO

ONCO.............................https://stockcharts.com/h-sc/ui?s=ONCO&p=W&b=5&g=0&id=p86431144783

ONCO...HERE WE GO

onco post split

I'm new to this one. Is it 30 million shares outstanding before or after the RS?

BB

? the Company agreed to convert all of Veru’s shares of Series A Preferred Stock of the Company into shares of Common Stock (the “Conversion Shares”). The Company If the aggregate unpaid principal outstanding under the April Veru Note and the September Veru Note and all accrued and unpaid interest thereon is repaid in cash on or before December 31, 2024, then the total principal balance under the September Veru Note that will be payable by the Company in satisfaction of its obligations under the September Veru Note will be reduced from $5,000,000 to $3,500,000.

Further, the Company has agreed that immediately after obtaining stockholder approval for its reverse stock split proposal at the Company’s Annual Meeting of Stockholders held on September 5, 2024, and having effectuated a reverse stock split of its outstanding shares of Common Stock and the conversion of all Series B Preferred Stock of the Company into shares of Common Stock, the Company agreed to convert all of Veru’s shares of Series A Preferred Stock of the Company into shares of Common Stock (the “Conversion Shares”). The Company has agreed that following the first anniversary of the issuance of the Series A Preferred Stock of the Company, the Company shall cause the Conversion Shares to not have any legend or other restrictions on transfer under the Securities Act of 1933.

The Company has additionally agreed to reimburse Veru for its out-of-pocket expenses, including legal fees, up to $7,500 in connection with the negotiation and execution of the A&R Forbearance Agreement.

On September 19, 2024, the Company entered into an Amended and Restated Forbearance Agreement with Veru (the “A&R Forbearance Agreement”) which amends and restates the Original Forbearance Agreement in its entirety. Pursuant to the A&R Forbearance Agreement, Veru will forbear from exercising its rights under both the April Veru Note and the September Veru Note, subject to the terms and conditions set forth below.

Pursuant to the A&R Forbearance Agreement, the April 2024 Forbearance Period continues to end on the earlier of (a) March 31, 2025 and (b) the occurrence of an Event of Default (as defined in the A&R Forbearance Agreement). The A&R Forbearance Agreement also extends the due date for the September Veru Note until the earlier to occur of: (i) June 30, 2025 or (ii) the occurrence of any Event of Default. The A&R Forbearance Agreement also effected certain modifications to the payment terms in the Original Forbearance Agreement and amended certain terms of the September Veru Note as summarized below.

Pursuant to the A&R Forbearance Agreement, the Company agreed to make the following required payments (the “Required Payments”) during the April 2024 Forbearance Period first to accrued and unpaid interest under the April Veru Note and then any remainder to the outstanding principal amount of the April Veru Note:

? Interest at the rate of 10% per annum shall accrue on any unpaid principal balance of the April Veru commencing on April 20, 2024 through the date that the outstanding principal balance under the April Veru Note is paid in full;

? monthly payments equal to 25% (increased from 15% in the Original Forbearance Agreement) of (i) the monthly cash receipts of Proteomedix for the licensing or sale of any products or services, (ii) monthly cash receipts of the Company or any of its subsidiaries for the sales of Proclarix anywhere in the world, and (iii) monthly cash receipts of the Company or any of its subsidiaries for milestone payments or royalties from Labcorp cash receipts of the Company or its subsidiaries from certain sale or licensing revenues or payments (the Ordinary Cash Revenue”), which increased amount shall begin on October 20, 2024 for cash receipts in September 2024;

? payment of 20% (increased from 10% in the Original Forbearance Agreement) of the net proceeds from certain financing or other transactions outside the ordinary course of business completed by the Company or any of its subsidiaries during the April 2024 Forbearance Period, which increased amount will begin for any net proceeds received after September 19, 2024;

? 15% of the Ordinary Cash Revenue generated in August 2024 shall be due to Veru on September 26, 2024; and

? The remaining balance of the April Veru Note will be due at the end of the April 2024 Forbearance Period.

1


The Company and Veru also agreed to the following amendments to the September Veru Note in the A&R Forbearance Agreement:

? As noted above, an extension of the maturity date to June 30, 2025;

? The accrual of interest at the rate of 10% per annum on any unpaid principal balance of the September Veru Note commencing on October 1, 2024 through the date that the outstanding principal balance under the September Veru Note is paid in full;

? Any amounts owed on the September Veru Note, including but not limited to unpaid principal and accrued interest, will be paid in cash or, upon the mutual written consent of Veru and the Company, in shares of the Company’s common stock or a combination of cash and the Company’s common stock;

? Following full repayment of all principal and interest under the April Veru Note, the Company will make the Required Payments first towards accrued and unpaid interest under the September Veru Note and then towards the remaining principal balance payable under the September Veru Note;

? If the aggregate unpaid principal outstanding under the April Veru Note and the September Veru Note and all accrued and unpaid interest thereon is repaid in cash on or before December 31, 2024, then the total principal balance under the September Veru Note that will be payable by the Company in satisfaction of its obligations under the September Veru Note will be reduced from $5,000,000 to $3,500,000.

Further, the Company has agreed that immediately after obtaining stockholder approval for its reverse stock split proposal at the Company’s Annual Meeting of Stockholders held on September 5, 2024, and having effectuated a reverse stock split of its outstanding shares of Common Stock and the conversion of all Series B Preferred Stock of the Company into shares of Common Stock, the Company agreed to convert all of Veru’s shares of Series A Preferred Stock of the Company into shares of Common Stock (the “Conversion Shares”). The Company has agreed that following the first anniversary of the issuance of the Series A Preferred Stock of the Company, the Company shall cause the Conversion Shares to not have any legend or other restrictions on transfer under the Securities Act of 1933.

The Company has additionally agreed to reimburse Veru for its out-of-pocket expenses, including legal fees, up to $7,500 in connection with the negotiation and execution of the A&R Forbearance Agreement.

The foregoing description of the A&R Forbearance Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the A&R Forbearance Agreement, a form of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference. For more information about the terms of the Original Forbearance Agreement, please see the Prior Form 8-K.

ONCO: Good plan!!

12:44 PM EDT, 09/20/2024 (MT Newswires) -- Onconetix (ONCO) said Friday that it will implement a 1-for-40 reverse stock split of its shares to help regain compliance with the minimum bid price requirement of $4.00 per share for initial listing on the Nasdaq Capital Market.

The shares will begin trading on a reverse stock split-adjusted basis on Sept. 24, the company said.

Watch for an entry ..reverse split completed. Let them beat it down first and then perhaps grab some

ONCO 10Q due MONDAY AUGUST 26

ONCO: Closed 37.52% UP in the Post-M of 7-17-24. (And evidently, for NO reasons whatsoever; but then, maybe its CHART made it go up, all by itself??? Who needs substantive 'reasons' behind anything anywhere???)
https://www.defenseworld.net/2024/07/17/advanced-oncotherapy-lonavo-share-price-crosses-below-200-day-moving-average-of-1-75.html
Watch out for that "200-day moving average", Folks!!!
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

ONCO.........................................https://stockcharts.com/h-sc/ui?s=ONCO&p=W&b=5&g=0&id=p86431144783

ONCO..........................https://stockcharts.com/h-sc/ui?s=ONCO&p=W&b=5&g=0&id=p86431144783

Thanks!

https://www.onconetix.com/products https://www.onconetix.com/publications

https://www.onconetix.com/pipeline

Not seeing a pipeline.....

https://finance.yahoo.com/quote/ONCO/?fr=sycsrp_catchall

Last Wednesday it briefly jumped above 50 cents and closed at $0.19 on Friday.>>>>So $ONCO looks like a consolidation phase to me and from Monday we could attack the dollar again, imo

oversold

The $ONCO consolidation phase should be over on Monday, Tuesday at the latest, then it should go up again to new highs.
https://www.stockscores.com/charts/charts/?ticker=onco

$ONCE trend has started (with consolidation phases)
https://stockcharts.com/sc3/ui/?s=ONCO

https://www.stockscores.com/charts/charts/?ticker=onco

wow

https://finviz.com/quote.ashx?t=ONCO&ty=c&ta=1&p=d

very strange,share issue?,insiders?,dunno,on watch,thanks bro!

Another round?

OCENTIX (ONCO) Stock Soars 171%: A Mysterious Surge with No Clear News https://stockmarketcoffee.com/ocentix-onco-stock-soars-171-a-mysterious-surge-with-no-clear-news/

Up 8% in after mkt,roll out news expected soon,ad campaign ect. Hopefully they do tv commercials

Name change already? That was SUPER quick imo

6 month hold on any selling for insiders,that’s awesome for us!!

Good to see someone else bought 100k shares,tutes and insiders are present,it’s so new I am not sure how accurate tho so I am not posting those numbers.

ONCO@.19,mkt cap3.36m,paid 75m,fda prescription drug starting commercialization,15m float,not optionable,new ticker started today,old ticker was BWV(blue water vaccines) looks like a Christmas present with the valuationwinkcould be a lump of coal,never know with these new tickers,

ONCO is the new ticker

BWV new 52 week low

BWV new 52 week low

BWV new 52 week low

BWV: My huge apologies for my MONSTER-belated reply here, Boss!!! (Big 'domestic' issues over here in S.D. for me today, so zero time for any substantive Markets actions on my part. Hope all here did WELL on this one --- likely in the Pre-Mkts., as you Guys do so well generally.)